AIM ImmunoTech Prices $2.0 Million Direct Offering

OCALA, Fla., May 31, 2024 — AIM ImmunoTech Inc. (NYSE American: AIM) revealed it has finalized a securities purchase agreement with a single institutional investor for the acquisition of 5,640,958 shares of common stock. The direct offering is priced at $0.363 per share. Additionally, in a simultaneous private placement, the company will issue unregistered Class A and Class B warrants, cumulatively allowing the purchase of up to 11,281,916 shares of common stock at the same per-share price.

The Class A and Class B warrants are each set with an exercise price of $0.363. Both types of warrants will be exercisable six months post-issuance, with the Class A warrants expiring after eighteen months and the Class B warrants expiring after five years from the initial exercise date. 

The expected gross revenue from this registered direct offering and concurrent private placement stands at approximately $2.0 million, prior to deducting placement agent fees and other offering-related expenses. Maxim Group LLC has been appointed as the sole placement agent for this transaction.

The common stock shares are being issued based on a shelf registration statement on Form S-3 (File No. 333-262280), which the U.S. Securities and Exchange Commission (SEC) declared effective on February 4, 2022. The shares will be offered exclusively through a prospectus, including a supplement, which is part of the effective registration statement. AIM ImmunoTech Inc. plans to file a prospectus supplement with the SEC, which will be available on the SEC’s website or by contacting Maxim Group LLC.

The warrants from the concurrent private placement, along with the shares issuable upon their exercise, are offered under Section 4(a)(2) of the Securities Act of 1933 and Regulation D. These securities have not been registered under the Act or applicable state laws, meaning they cannot be offered or sold in the U.S. without meeting specific registration requirements or exemptions.

This announcement does not constitute an offer to sell or a solicitation to buy any securities, nor will there be any sales in jurisdictions where such offers or sales are illegal without appropriate registration or qualification under local securities laws.

About AIM ImmunoTech Inc.

AIM ImmunoTech Inc. is a pharmaceutical company specializing in immunology, focusing on developing treatments for various cancers, immune disorders, and viral diseases, such as COVID-19. The company's flagship product, Ampligen® (rintatolimod), is an investigational drug with broad-spectrum activity, currently undergoing clinical trials for significant global health issues.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!